netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 5: Infections - Full Chapter
Notes:

Please note that Primary and Secondary Care have separate antimicrobial guidelines; Secondary Care utilises a UHNM Trust-specific antimicrobial formulary (note that the UHNM antimicrobial guidelines [microguide] can also be downloaded on smartphones).

These can be found at:

For Primary Care, the Antimicrobial Guidelines can be accessed on netFormulary link: http://www.northstaffordshirejointformulary.nhs.uk/docs/misc/Antimicrobial%20guidelines%202019%20Final%20version.pdf

For Secondary Care on the UHNM intranet by following: http://uhnm/clinicians/clinical-guidance/clinical-guidelines-and-pathways/antimicrobial/

Patients with HIV are treated according to the NICE accredited British HIV Association (BHIVA) guidelines which can be found at www.bhiva.org

 Details...
05.03.03.01  Expand sub section  Chronic hepatitis B
 note 

All medicines for the treatment of viral hepatitis are funded by NHS England

Adefovir Dipivoxil (Hepsera)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Adefovir Dipivoxil Tablets 10mg

Restriction: In line with NICE Guidance

This is a Specialised Drug which would not be routinely commissioned by CCGs for Hepatitis B. This would go through the CCGs Individual Funding Request (IFR).

 
Link  NICE CG165: Hepatitis B (chronic): diagnosis and management
Link  NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
   
Entecavir Monohydrate
(Baraclude)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Entecavir Monohydrate Tablets 500mcg
Entecavir Monohydrate Tablets 1mg

Restriction: In line with NICE Guidance

This is an NHS England Specialised Commissioning Drug for Hepatitis B

 
Link  NICE CG165: Hepatitis B (chronic): diagnosis and management
Link  NICE TA153: Entecavir for the treatment of chronic hepatitis B
   
Tenofovir Disproxil
(Viread)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Tenofovir Disproxil Tablets 123mg
Tenofovir Disproxil Tablets 163mg
Tenofovir Disproxil Tablets 204mg
Tenofovir Disproxil Tablets 245mg
Tenofovir Disproxil Granules 33mg/g

Restriction: In line with NICE Guidance
This is an NHS England Specialised Commissioning Drug for Hepatitis B +/- other anti-retroviral drugs.

7.5 scoops of granules contains approx. 245 mg tenofovir disoproxil (as fumarate).

 

 
Link  NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary